A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike protein
Sharon L. Schendel, Xiaoying Yu, Peter Halfmann, Jarjapu Mahita, Brendan Ha, Kathryn M. Hastie, Haoyang Li, Daniel Bedinger, Camille Troup, Kan Li, Natalia A. Kuzmina, Jordi B. Torrelles, Jennifer E. Munt, Melissa Mattocks, Mary Osei-Twum, Heather Callaway, Stephen T. Reece, Anne Palser, Paul Kellam, S. Moses Dennison, Richard H.C. Huntwork, Gillian Q. Horn, Milite Abraha, Elizabeth Feeney, Luis Martínez‐Sobrido, Paula A. Pino, Amberlee Hicks, Chengjin Ye, Jun-Gyu Park, Billie Maingot, Sivakumar Periasamy, Michael L. Mallory, Trevor Scobey, Marie-Noelle Lepage, Natalie St-Amant, S. Khan, Anaïs Gambiez, Ralph S. Baric, Alexander Bukreyev, Luc Gagnon, Timothy Germann, Yoshihiro Kawaoka, Georgia D. Tomaras, Bjoern Peters, Erica Ollmann Saphire
Abstract
The Coronavirus Immunotherapeutic Consortium (CoVIC) conducted side-by-side comparisons of over 400 anti-SARS-CoV-2 spike therapeutic antibody candidates contributed by large and small companies as well as academic groups on multiple continents. Nine reference labs analyzed antibody features, including in vivo protection in a mouse model of infection, spike protein affinity, high-resolution epitope binning, ACE-2 binding blockage, structures, and neutralization of pseudovirus and authentic virus infection, to build a publicly accessible dataset in the database CoVIC-DB. High-throughput, high-resolution binning of CoVIC antibodies defines a broad and predictive landscape of antibody epitopes on the SARS-CoV-2 spike protein and identifies features associated with durable potency against multiple SARS-CoV-2 variants of concern and high in vivo efficacy. Results of the CoVIC studies provide a guide for selecting effective and durable antibody therapeutics and for immunogen design as well as providing a framework for rapid response to future viral disease outbreaks.